Akums Drugs
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Akums Drugs' management has expressed a confident outlook, primarily driven by robust performance in its Contract Development and Manufacturing Organization (CDMO) segment and a strategic pivot towards higher-margin niche formulations. The company is focusing on volume-led growth, supported by recent capacity expansions and a disciplined approach to inorganic opportunities. This aligns with Vista's forecast of stable revenue growth and improving margins, as the CDMO business is expected to be the primary growth engine, benefiting from strong volume growth and a recovery in API pricing. Additionally, the anticipated contributions from the Zambia joint venture and expansion into European markets are expected to enhance revenue visibility and profitability. However, potential headwinds include raw material supply constraints due to government restrictions and ongoing volatility in API pricing. Overall, the industry is experiencing favorable dynamics, with improving pricing power and a projected CAGR of 10.86%, which supports Akums' growth trajectory. Over the next 12-24 months, key opportunities lie in scaling international operations and optimizing product mix, while watchpoints include managing customer concentration risks and navigating geopolitical challenges affecting raw material costs
Why We Like This Stock
- Strong performance in the CDMO segment is driving revenue growth and margin expansion
- Strategic international expansion, particularly in Zambia and Europe, is expected to enhance revenue visibility
- Management's focus on high-margin niche formulations aligns with improving industry dynamics
Things To Watch Out For
- Raw material supply constraints due to government restrictions may impact production costs
- Ongoing volatility in API pricing poses risks to profitability
- High customer concentration could lead to revenue instability if key clients face challenges
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 4,178 | 4,118 | 4,359 | 4,669 | 5,189 |
| Profit Before Tax (Cr.) | -19 | 325 | 402 | 431 | 498 |
| PBT Margin | -0.5% | 7.9% | 9.2% | 9.2% | 9.6% |
| Net Profit (Cr.) | -136 | 248 | 304 | 329 | 378 |
| Earnings Per Share | -9.2 | 15.8 | 19.8 | 21.4 | 24.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Citigroup | ▲ Buy | 860 | 18-Aug-2026 |
| ICICI Securities | ▲ Buy | 850 | 11-Aug-2026 |
Company Overview
Show Company Profile
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.